Author

K. Risner

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:human· 2 Assay:bulk RNA-seq· 1

Frequent Co-Authors

A. Narayanan· 3 shared A. Bakovic· 2 shared N. Bhalla· 2 shared A. Alape· 1 shared A. C. Castillo· 1 shared A. Gomez· 1 shared A. Hernandez· 1 shared A. Sanchez· 1 shared

Activity by Year

2020-2020 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

A. Narayanan

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Brilacidin, a COVID-19 Drug Candidate, Exhibits Potent In Vitro Antiviral Activity Against SARS-CoV-2

A. Bakovic, K. Risner, N. Bhalla, F. Alem, T. L. Chang, W. Weston, J. A. Harness, A. Narayanan

This paper shows brilacidin, a synthetic small molecule, strongly inhibits SARS-CoV-2 in cell cultures and works well with remdesivir.

bioRxiv · Oct 29, 2020 · PreprintMicrobiology

Development and pre-clinical characterization of two therapeutic equine formulations towards SARS-CoV-2 proteins for the potential treatment of COVID-19

G. Leon, M. Herrera, M. Vargas, M. Arguedas, A. Sanchez, A. Segura, A. Gomez, G. Solano, E. Corrales-Aguilar, K. Risner, A. Narayanan, C. Bailey, M. Villalta, A. Hernandez, A. Sanchez, , A. Alape

This paper develops and pre-clinically evaluates two equine-derived anti-SARS-CoV-2 polyclonal formulations for potential COVID-19 treatment, showing high neutralizing capacity against SARS-CoV-2 infection.

bioRxiv · Oct 17, 2020 · PreprintMicrobiology

Maraviroc inhibits SARS-CoV-2 multiplication and s-protein mediated cell fusion in cell culture

K. Risner, K. V. Tieu, Y. Wang, M. Getz, A. Bakovic, N. Bhalla, S. Nathan, D. E. Conway, P. Macklin, A. Narayanan

This study identifies four FDA-approved drugs that inhibit SARS-CoV-2 infection in cell culture, with Maraviroc showing reduced S-protein mediated cell fusion.

bioRxiv · Aug 12, 2020 · PreprintMicrobiology